Table 1 Patient characteristics for patients with grass pollen allergy with and without sublingual immunotherapy (SLIT)
From: HealthSWEDE: costs with sublingual immunotherapy—a Swedish questionnaire study
Total (n = 295) | SLIT (n = 177) | Reference population (n = 118) | |
|---|---|---|---|
Men/women | 49%/51% | 55%/45% | 41%/59% |
Age, mean years (SD) | 36.5 (11.1) | 37.2 (11.6) | 35.3 (10.2) |
Employed, n (%) | 235 (80%) | 146 (82%) | 89 (75%) |
Daily smoker, n (%) | 6 (2%) | 5 (3%) | 1 (< 1%) |
Previous smoker, n (%) | 52 (18%) | 37 (21%) | 15 (13%) |
Self-reported asthma, n (%) | 97 (33%) | 57 (32%) | 40 (34%) |
Self-reported eczema, n (%) | 53 (18%) | 30 (17%) | 23 (19%) |
Self-reported use of medications against nasal and or eye problem during the last year, n (%) | 282 (96%) | 168 (95%) | 114 (97%) |
Out of thosea | |||
Systemic corticosteroids, n (%) | 69 (24%) | 24 (14%) | 45(41%) |
Nasal steroid spray, n (%) | 224 (79%) | 122 (73%) | 102 (89%) |
Nasal antihistamine spray, n (%) | 92 (33%) | 41 (24%) | 51 (45%) |
Antihistamine, oral, n (%) | 245 (87%) | 138 (82%) | 107 (94%) |